Ironwood Pharmaceuticals Inc

NASDAQ:IRWDUnited States

Oct 28, 2024

Show headlines and story abstract

• Ironwood Says Apraglutide Shows 'Consistent Treatment Effect' in Short Bowel Syndrome; Shares Rise, from 9:42AM ET on Monday Oct 28, 2024 by MT Newswires

  9:42AM ET on Monday Oct 28, 2024 by MT Newswires
  Companies Mentioned: IRWD
  09:42 AM EDT, 10/28/2024 (MT Newswires) -- Ironwood Pharmaceuticals (IRWD) said Monday that data from a phase 3 trial assessing apraglutide in adults with short bowel syndrome with intestinal failure showed a "consistent treatment effect." The consi...

• DJ Ironwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study, from 8:09AM ET on Monday Oct 28, 2024 by Dow Jones

  8:09AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: IRWD
  
  By Jasmine Li
  
  Shares of Ironwood Pharmaceuticals rose after it reported positive trial results for its treatment for short bowel syndrome with intestinal failure.
  
  

• Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024, from 7:00AM ET on Monday Oct 28, 2024 by Dow Jones

  7:00AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: IRWD
  
  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the assessment of the data from the Phase III STARS clinical trial of apraglutide; the efficacy, safety and tolerability of apraglutide; Ironwood's plan to submit an NDA and marketing applications to other regulatory filings for apraglutide and the expected timing to complete U.S. regulatory submission; the estimated adult population who suffer from SBS-IF in the U.S., Europe and Japan; that the findings from the Phase III STARS clinical trial reinforce the clinical profile of once-weekly apraglutide and confirm consistency of treatment effect across different subgroups; and the potential of apraglutide to be available as the first once-weekly treatment option for patients with SBS who are dependent on PS. These forward-looking statements speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of our products and product candidates; the risk that clinical programs and studies, including for products and product candidates may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our completed nonclinical studies and clinical trials may not be replicated in later trials and earlier-stage clinical trials may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of regulatory approval; the risk that apraglutide will not be approved by the FDA or other regulatory agencies; the risk of competition or that new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates, that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; the risk that the development of any of our products is not successful or that any of our product candidates does not receive regulatory approval or is not successfully commercialized; outcomes in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug application litigation; and the risks listed under the heading "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2023, and in our subsequent Securities and Exchange Commission filings.